General Information of This Antigen
Antigen ID
TAR0UYFIF
Antigen Name
Epidermal growth factor receptor (EGFR)
Gene Name
EGFR
Gene ID
1956
Synonym
ERBB; ERBB1; HER1; Proto-oncogene c-ErbB-1;Receptor tyrosine-protein kinase erbB-1
Sequence
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA

    Click to Show/Hide
Family
Tyr protein family
Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin- binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration. Plays a role in enhancing learning and memory performance. Plays a role in mammalian pain signaling (long-lasting hypersensitivity).

    Click to Show/Hide
Uniprot Entry
EGFR_HUMAN
HGNC ID
HGNC:3236
KEGG ID
hsa:1956
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
1711/425 scFv-SNAP
ADC Info ADC Name Payload Target Linker Ref
1711 (scFv)-SNAP-AuriF
Auristatin F
Microtubule (MT)
BG based linker
[1]
9G8-7D12-Fc
ADC Info ADC Name Payload Target Linker Ref
S7 ADC
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[2]
9G8-7D12-Fc with E430G
ADC Info ADC Name Payload Target Linker Ref
S7-E430G ADC
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[2]
Anti-EGFR Ab1
ADC Info ADC Name Payload Target Linker Ref
Ab1-mcMMAF
Monomethyl auristatin F
Microtubule (MT)
Maleimido-caproyl
[3]
Anti-EGFR Ab3
ADC Info ADC Name Payload Target Linker Ref
Ab3-mcMMAF
Monomethyl auristatin F
Microtubule (MT)
Maleimido-caproyl
[3]
Anti-EGFR AbA
ADC Info ADC Name Payload Target Linker Ref
AbA-vcMMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[3]
AbA-mcMMAE
Monomethyl auristatin E
Microtubule (MT)
Maleimido-caproyl
[3]
Anti-EGFR huFc
ADC Info ADC Name Payload Target Linker Ref
HuFc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gly3-Val-Cit-PABC
[4]
Anti-EGFR mAb
ADC Info ADC Name Payload Target Linker Ref
Anti-EGFR-Sulfo-SMCC-DM1
Mertansine DM1
Microtubule (MT)
Sulfo-SMCC
[5]
Anti-EGFR-Ala-Ala-IGN
Indolinobenzodiazepine dimer
Human Deoxyribonucleic acid (hDNA)
Ala-Ala dipeptide
[6]
Anti-EGFR-Val-Gln-IGN
Indolinobenzodiazepine dimer
Human Deoxyribonucleic acid (hDNA)
Val-Gln dipeptide linker
[6]
EGFR-ADC 13a
PBD dimer 14a
Human Deoxyribonucleic acid (hDNA)
Adipic acid-Val-Ala-PABC
[7]
EGFR-ADC 13b
PBD dimer 14b
Human Deoxyribonucleic acid (hDNA)
Adipic acid-Val-Ala-PABC
[7]
EGFR-ADC 13c
PBD dimer 14c
Human Deoxyribonucleic acid (hDNA)
Adipic acid-Val-Ala-PABC
[7]
Anti-EGFR mAb 40H3
ADC Info ADC Name Payload Target Linker Ref
40H3-Tesirine
SG3199
Human Deoxyribonucleic acid (hDNA)
Mal-PEG8-Val-Ala-PABC
[8]
40H3-MCVCPAB-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[8]
40H3-CL2A-SN38
Active metabolite of irinotecan SN38
DNA topoisomerase 1 (TOP1)
CL2A
[8]
40H3-SMCC-DM1
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[8]
40H3-Deruxtecan
DX-8951 derivative (DXd)
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
[8]
Anti-EGFR mAb hR3-YTE
ADC Info ADC Name Payload Target Linker Ref
SHR-A1307
SHR152852
Microtubule (MT)
L2-MC
[9]
Anti-EGFR mAb LA22
ADC Info ADC Name Payload Target Linker Ref
LA22-MMC
Mitomycin C
Human Deoxyribonucleic acid (hDNA)
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)
[10]
Anti-EGFR mAb rat IgG2a
ADC Info ADC Name Payload Target Linker Ref
Anti-EGFR-PEG4-Mal-DM1
Mertansine DM1
Microtubule (MT)
PEG4-Mal
[11]
ADC Info ADC Name Payload Target Linker Ref
MYK-3
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[12]
BA03-MC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[12]
BA03-MCC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[12]
Cetuximab
ADC Info ADC Name Payload Target Linker Ref
Cetuximab sarotalocan
IRDye 700DX
Undisclosed
Linear alkyl/alkoxy linker
[13]
Cetuximab- (FGX16-11)
FGX8-46
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala-PABC
[14]
Hu-Alpha-EGFR-172
IMSA172
Stimulator of interferon genes protein (STING1)
Mc-Val-Cit-PABC
[15]
C-IgG-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gly3-Val-Cit-PABC
[4]
Cetuximab-Puromycin
Puromycin
Ribosome (RB)
Succinimidyl acetylthiopropionate (SATP)
[16]
Cet-DM1
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[17]
MAb-DMBA-SIL-MMAE
Monomethyl auristatin E
Microtubule (MT)
DMBA-SIL
[18]
MAb-DMBA-SIL-Dox
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
DMBA-SIL
[18]
Cetuximab-Val-Cit-Dox
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Mc-Val-Cit-PABC
[19]
Erbitux-MHT-71
Auristatin F
Microtubule (MT)
MHT-71
[20]
EGFR-ADC-07 (DAR8)
EGFR-ADC-07(DAR8) payload
Undisclosed
EGFR-ADC-07(DAR8) linker
[21]
EGFR-ADC-07 (DAR4)
EGFR-ADC-07(DAR4) payload
Undisclosed
EGFR-ADC-07(DAR4) linker
[21]
EGFR-ADC-08 (DAR8)
EGFR-ADC-08(DAR8) payload
Undisclosed
EGFR-ADC-08(DAR8) linker
[21]
EGFR-ADC-08 (DAR4)
EGFR-ADC-08(DAR4) payload
Undisclosed
EGFR-ADC-08(DAR4) linker
[21]
EGFR-ADC-32 (DAR4)
EGFR-ADC-32(DAR4) payload
Undisclosed
EGFR-ADC-32(DAR4) linker
[21]
Cetuximab-Comound (Ia)
NeoDegrader P1
Protein cereblon (CRBN)
Cetuximab-Comound (Ia) linker
[22]
WO2017089895A1 ADC64
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC64 linker
[23]
WO2017089895A1 ADC65
Monomethyl auristatin E
Microtubule (MT)
WO2017089895A1_ADC65 linker
[23]
WO2017089895A1 ADC66
Monomethyl auristatin F
Microtubule (MT)
WO2017089895A1_ADC66 linker
[23]
Cet-ZA ADC
Zoledronic acid
Geranylgeranyl pyrophosphate synthase (GGPS1)
Undisclosed
[24]
Quinoin cetuximab immunoconjugate
Quinoin
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)
[25]
ITcetuximab
Saporin
Microtubule (MT)
Undisclosed
[26]
Cet-TPL
Triptolide
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
N-hydroxysuccinimide based linker
[27]
Cetuximab-DNA conjugate
DNA mimics
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[28]
WO2022078260A1 ADC-9
Ln-D2
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-9 linker
[29]
WO2022078260A1 ADC-10
Ln-D7
DNA topoisomerase 1 (TOP1)
WO2022078260A1_ADC-10 linker
[29]
EGFR-MMAU ADC
Glucuronyl-monomethyl-auristatin E (MMAU)
Microtubule (MT)
Mc-Val-Cit-PABC
[30]
Cetux Cys-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
Cetuximab-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[32]
CTX-MMAE
Monomethyl auristatin E
Microtubule (MT)
PD-Val-Cit-PABC
[33]
EGFR ADC-21
Monomethyl auristatin E
Microtubule (MT)
Vinylsulfonamide based linker 15
[34]
EGFR ADC-22
Monomethyl auristatin E
Microtubule (MT)
Vinylsulfonamide based linker 16
[34]
EGFR ADC-23
Monomethyl auristatin E
Microtubule (MT)
Vinylsulfonamide based linker 17
[34]
WO2017089890A1 ADC64
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC64 linker
[35]
WO2017089890A1 ADC65
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC65 linker
[35]
WO2017089890A1 ADC66
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC66 linker
[35]
Cetuximab-Compound 9
Mertansine DM1
Microtubule (MT)
Cetuximab-Compound 9 linker
[36]
Cetuximab-Compound 17
Mertansine DM4
Microtubule (MT)
Cetuximab-Compound 17 linker
[36]
Cetuximab-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Cetuximab-Compound 25 linker
[36]
Cetuximab-Compound 31
Auristatin 0101
Microtubule (MT)
Cetuximab-Compound 31 linker
[36]
Cetuximab-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Cetuximab-Compound 36 linker
[36]
Cetuximab-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Cetuximab-Compound 43 linker
[36]
Cetuximab-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Cetuximab-Compound 49 linker
[36]
Cetuximab-Compound 55
Mertansine DM1
Microtubule (MT)
Cetuximab-Compound 55 linker
[36]
Cetuximab-Compound 59
Mertansine DM4
Microtubule (MT)
Cetuximab-Compound 59 linker
[36]
Cetuximab-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Cetuximab-Compound 64 linker
[36]
Cetuximab-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Cetuximab-Compound 69 linker
[36]
Cetuximab-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Cetuximab-Compound 74 linker
[36]
Cetuximab-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Cetuximab-Compound 75 linker
[36]
Cetuximab-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Cetuximab-Compound 76 linker
[36]
Cetuximab-Compound 77
Mertansine DM1
Microtubule (MT)
Cetuximab-Compound 77 linker
[36]
Cetuximab-Compound 78
Auristatin 0101
Microtubule (MT)
Cetuximab-Compound 78 linker
[36]
Cetuximab-Compound 79
Auristatin 0101
Microtubule (MT)
Cetuximab-Compound 79 linker
[36]
Cetuximab-Compound 80
Mertansine DM4
Microtubule (MT)
Cetuximab-Compound 80 linker
[36]
CN114917361A ADC-1
CN114917361A ADC-1 payload
Undisclosed
CN114917361A ADC-1 linker
[37]
CN114917361A ADC-6
CN114917361A ADC-6 payload
Undisclosed
CN114917361A ADC-6 linker
[37]
CN114917361A ADC-11
CN114917361A ADC-11 payload
Undisclosed
CN114917361A ADC-11 linker
[37]
CN114917361A ADC-13
CN114917361A ADC-13 payload
Undisclosed
CN114917361A ADC-13 linker
[37]
CN114917361A ADC-16
CN114917361A ADC-16 payload
Undisclosed
CN114917361A ADC-16 linker
[37]
CN114917361A ADC-19
CN114917361A ADC-19 payload
Undisclosed
CN114917361A ADC-19 linker
[37]
CN114917361A ADC-21
CN114917361A ADC-21 payload
Undisclosed
CN114917361A ADC-21 linker
[37]
CN114917361A ADC-25
CN114917361A ADC-25 payload
Undisclosed
CN114917361A ADC-25 linker
[37]
CN114917361A ADC-27
CN114917361A ADC-27 payload
Undisclosed
CN114917361A ADC-27 linker
[37]
CN114917361A ADC-30
CN114917361A ADC-30 payload
Undisclosed
CN114917361A ADC-30 linker
[37]
CN114917361A ADC-33
CN114917361A ADC-33 payload
Undisclosed
CN114917361A ADC-33 linker
[37]
CN114917361A ADC-36
CN114917361A ADC-36 payload
Undisclosed
CN114917361A ADC-36 linker
[37]
CN114917361A ADC-39
CN114917361A ADC-39 payload
Undisclosed
CN114917361A ADC-39 linker
[37]
CN114917361A ADC-41
CN114917361A ADC-41 payload
Undisclosed
CN114917361A ADC-41 linker
[37]
CN114917361A ADC-44
CN114917361A ADC-44 payload
Undisclosed
CN114917361A ADC-44 linker
[37]
CN114917361A ADC-47
CN114917361A ADC-47 payload
Undisclosed
CN114917361A ADC-47 linker
[37]
CN114917361A ADC-50
CN114917361A ADC-50 payload
Undisclosed
CN114917361A ADC-50 linker
[37]
CN114917361A ADC-55
CN114917361A ADC-55 payload
Undisclosed
CN114917361A ADC-55 linker
[37]
CN114917361A ADC-58
CN114917361A ADC-58 payload
Undisclosed
CN114917361A ADC-58 linker
[37]
CN114917361A ADC-61
CN114917361A ADC-61 payload
Undisclosed
CN114917361A ADC-61 linker
[37]
CN114917361A ADC-64
CN114917361A ADC-64 payload
Undisclosed
CN114917361A ADC-64 linker
[37]
CN114917361A ADC-67
CN114917361A ADC-67 payload
Undisclosed
CN114917361A ADC-67 linker
[37]
CN114917361A ADC-70
CN114917361A ADC-70 payload
Undisclosed
CN114917361A ADC-70 linker
[37]
CN114917361A ADC-73
CN114917361A ADC-73 payload
Undisclosed
CN114917361A ADC-73 linker
[37]
CN114917361A ADC-76
CN114917361A ADC-76 payload
Undisclosed
CN114917361A ADC-76 linker
[37]
CN114917361A ADC-79
CN114917361A ADC-79 payload
Undisclosed
CN114917361A ADC-79 linker
[37]
CN114917361A ADC-82
CN114917361A ADC-82 payload
Undisclosed
CN114917361A ADC-82 linker
[37]
Cetuximab based antibody-drug conjugate
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[38]
Cetuximab (Fc/Fab labeled with Neu5NAz)
ADC Info ADC Name Payload Target Linker Ref
Cetux Fc/Fab-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
Cetuximab (LC)
ADC Info ADC Name Payload Target Linker Ref
Cetuximab (LC)-2i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LC)-2i linker
[39]
Cetuximab (LC)-3i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LC)-3i linker
[39]
Cetuximab (LC)-4i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LC)-4i linker
[39]
Cetuximab (LC)-6e
Monomethyl auristatin E
Microtubule (MT)
Cetuximab(LC)-6e linker
[39]
Cetuximab (LC)-amanitin
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Cetuximab(LC)-amanitin linker
[39]
Cetuximab (LC) G7-CVIM
ADC Info ADC Name Payload Target Linker Ref
ADC14-0810
Monomethyl auristatin F
Microtubule (MT)
ADC14-0810 linker
[39]
Cetuximab (LC) G7-CVIM-3i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LC) G7-CVIM-3i linker
[39]
Cetuximab (LC) G7-CVIM-4i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LC) G7-CVIM-4i linker
[39]
Cetuximab (LC) G7-CVIM-6e
Monomethyl auristatin E
Microtubule (MT)
Cetuximab(LC) G7-CVIM-6e linker
[39]
Cetuximab (LC) G7-CVIM-amanitin
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Cetuximab(LC) G7-CVIM-amanitin linker
[39]
Cetuximab (LV) G7-CVIM
ADC Info ADC Name Payload Target Linker Ref
LCB14-0645
Monomethyl auristatin F
Microtubule (MT)
LCB14-0645 linker
[39]
Cetuximab (LV) G7-CVIM-3i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LV) G7-CVIM-3i linker
[39]
Cetuximab (LV) G7-CVIM-4i
Monomethyl auristatin F
Microtubule (MT)
Cetuximab(LV) G7-CVIM-4i linker
[39]
Cetuximab (LV) G7-CVIM-6e
Monomethyl auristatin E
Microtubule (MT)
Cetuximab(LV) G7-CVIM-6e linker
[39]
Cetuximab (LV) G7-CVIM-amanitin
Alpha-amanitin
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
Cetuximab(LV) G7-CVIM-amanitin linker
[39]
Cetuximab Fab
ADC Info ADC Name Payload Target Linker Ref
C-Fab-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gly3-Val-Cit-PABC
[4]
Cetuximab Fab (conjugate to glycan residues)
ADC Info ADC Name Payload Target Linker Ref
Cetux Fab-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
Demupitamab
ADC Info ADC Name Payload Target Linker Ref
Demupitamab-ADC-Tb5-1
Demupitamab-ADC-Tb5-1 payload
Undisclosed
Demupitamab-ADC-Tb5-1 linker
[21]
Demupitamab-ADC-Tb5-2
Demupitamab-ADC-Tb5-2 payload
Undisclosed
Demupitamab-ADC-Tb5-2 linker
[21]
Depatuxizumab
ADC Info ADC Name Payload Target Linker Ref
Depatuxizumab mafodotin
Monomethyl auristatin F
Microtubule (MT)
Maleimido-caproyl
[40]
Depatuxizumab-ADC-Tb5-1
Depatuxizumab-ADC-Tb5-1 payload
Undisclosed
Depatuxizumab-ADC-Tb5-1 linker
[21]
Depatuxizumab-ADC-Tb5-2
Depatuxizumab-ADC-Tb5-2 payload
Undisclosed
Depatuxizumab-ADC-Tb5-2 linker
[21]
WO2017089890A1 ADC73
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC73 linker
[35]
WO2017089890A1 ADC74
Monomethyl auristatin E
Microtubule (MT)
WO2017089890A1_ADC74 linker
[35]
WO2017089890A1 ADC75
Monomethyl auristatin F
Microtubule (MT)
WO2017089890A1_ADC75 linker
[35]
Depatuxizumab S238C
ADC Info ADC Name Payload Target Linker Ref
ABBV-322
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala
[41]
EGFR Ab-L
ADC Info ADC Name Payload Target Linker Ref
RN765C
Auristatin 0101
Microtubule (MT)
AcLys-Val-Cit-PABC
[42]
ERC6 bispecific Anti-ody (fuse Anti-cotinine scFv to cetuximab CH3 domain)
ADC Info ADC Name Payload Target Linker Ref
Cotinine-duocarmycin
Duocarmycin Sa
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Cit-PABC-DMAE
[43]
ADC Info ADC Name Payload Target Linker Ref
Fcab-1-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gly3-Val-Cit-PABC
[4]
ADC Info ADC Name Payload Target Linker Ref
Fcab-2-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gly3-Val-Cit-PABC
[4]
ADC Info ADC Name Payload Target Linker Ref
Fcab-3-MMAE
Monomethyl auristatin E
Microtubule (MT)
Gly3-Val-Cit-PABC
[4]
Futuximab
ADC Info ADC Name Payload Target Linker Ref
Futuximab-ADC-Tb5-1
Futuximab-ADC-Tb5-1 payload
Undisclosed
Futuximab-ADC-Tb5-1 linker
[21]
Futuximab-ADC-Tb5-2
Futuximab-ADC-Tb5-2 payload
Undisclosed
Futuximab-ADC-Tb5-2 linker
[21]
Fv-LDP-D3
ADC Info ADC Name Payload Target Linker Ref
Fv-LDP-D3-AE
Lidamycin
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[44]
Glyco-engineered cetuximab
ADC Info ADC Name Payload Target Linker Ref
Cetux Cys-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
Glyco-engineered cetuximab Fab
ADC Info ADC Name Payload Target Linker Ref
Glyco-cetuximab Fab-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
Glyco-engineered cetuximab Fc/Fab
ADC Info ADC Name Payload Target Linker Ref
Cetux Fc/Fab-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
hu-alpha-EGFR(ACVC), cetuximab with A114C and V205C mutations
ADC Info ADC Name Payload Target Linker Ref
Hu-Alpha-EGFR (ACVC)-172
IMSA172
Stimulator of interferon genes protein (STING1)
Mc-Val-Cit-PABC
[15]
Imgatuzumab
ADC Info ADC Name Payload Target Linker Ref
Imgatuzumab-ADC-Tb5-1
Imgatuzumab-ADC-Tb5-1 payload
Undisclosed
Imgatuzumab-ADC-Tb5-1 linker
[21]
Imgatuzumab-ADC-Tb5-2
Imgatuzumab-ADC-Tb5-2 payload
Undisclosed
Imgatuzumab-ADC-Tb5-2 linker
[21]
ADC Info ADC Name Payload Target Linker Ref
MRG-003
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[45]
Laprituximab
ADC Info ADC Name Payload Target Linker Ref
Laprituximab-ADC-Tb5-1
Laprituximab-ADC-Tb5-1 payload
Undisclosed
Laprituximab-ADC-Tb5-1 linker
[21]
Laprituximab-ADC-Tb5-2
Laprituximab-ADC-Tb5-2 payload
Undisclosed
Laprituximab-ADC-Tb5-2 linker
[21]
Laprituximab emtansine
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[46]
Losatuxizumab
ADC Info ADC Name Payload Target Linker Ref
Losatuxizumab vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[47]
Losatuxzumab
ADC Info ADC Name Payload Target Linker Ref
Losatuxzumab-ADC-Tb5-1
Losatuxzumab-ADC-Tb5-1 payload
Undisclosed
Losatuxzumab-ADC-Tb5-1 linker
[21]
Losatuxzumab-ADC-Tb5-2
Losatuxzumab-ADC-Tb5-2 payload
Undisclosed
Losatuxzumab-ADC-Tb5-2 linker
[21]
ADC Info ADC Name Payload Target Linker Ref
LR004-Val-Cit-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[48]
LR-DM1
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[49]
ADC Info ADC Name Payload Target Linker Ref
AVID-100
Mertansine DM1
Microtubule (MT)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[50]
Matuzumab
ADC Info ADC Name Payload Target Linker Ref
Matuzumab-ADC-Tb5-1
Matuzumab-ADC-Tb5-1 payload
Undisclosed
Matuzumab-ADC-Tb5-1 linker
[21]
Matuzumab-ADC-Tb5-2
Matuzumab-ADC-Tb5-2 payload
Undisclosed
Matuzumab-ADC-Tb5-2 linker
[21]
Modotuximab
ADC Info ADC Name Payload Target Linker Ref
Modotuximab-ADC-Tb5-1
Modotuximab-ADC-Tb5-1 payload
Undisclosed
Modotuximab-ADC-Tb5-1 linker
[21]
Modotuximab-ADC-Tb5-2
Modotuximab-ADC-Tb5-2 payload
Undisclosed
Modotuximab-ADC-Tb5-2 linker
[21]
mu-alpha-EGFR
ADC Info ADC Name Payload Target Linker Ref
Mu-Alpha-EGFR-172
IMSA172
Stimulator of interferon genes protein (STING1)
Mc-Val-Cit-PABC
[15]
ADC Info ADC Name Payload Target Linker Ref
NC-6201
E7974
Microtubule (MT)
Undisclosed
[51]
Necitumumab
ADC Info ADC Name Payload Target Linker Ref
Necitumumab-ADC-Tb5-1
Necitumumab-ADC-Tb5-1 payload
Undisclosed
Necitumumab-ADC-Tb5-1 linker
[21]
Necitumumab-ADC-Tb5-2
Necitumumab-ADC-Tb5-2 payload
Undisclosed
Necitumumab-ADC-Tb5-2 linker
[21]
Nimotuzumab
ADC Info ADC Name Payload Target Linker Ref
Nimotuzumab-ADC-24-1
Nimotuzumab-ADC-24-1 payload
Undisclosed
Nimotuzumab-ADC-24-1 linker
[52]
Nimotuzumab-ADC-24-2
Nimotuzumab-ADC-24-2 payload
Undisclosed
Nimotuzumab-ADC-24-2 linker
[52]
Nimotuzumab-ADC-24-3
Nimotuzumab-ADC-24-3 payload
Undisclosed
Nimotuzumab-ADC-24-3 linker
[52]
Nimotuzumab-ADC-24-4
Nimotuzumab-ADC-24-4 payload
Undisclosed
Nimotuzumab-ADC-24-4 linker
[52]
Nimotuzumab-ADC-24-5
Nimotuzumab-ADC-24-5 payload
Undisclosed
Nimotuzumab-ADC-24-5 linker
[52]
Nimotuzumab-ADC-24-6
Nimotuzumab-ADC-24-6 payload
Undisclosed
Nimotuzumab-ADC-24-6 linker
[52]
Nimotuzumab-ADC-24-7
Nimotuzumab-ADC-24-7 payload
Undisclosed
Nimotuzumab-ADC-24-7 linker
[52]
Nimotuzumab-ADC-24-8
Nimotuzumab-ADC-24-8 payload
Undisclosed
Nimotuzumab-ADC-24-8 linker
[52]
Nimotuzumab-ADC-24-9
Nimotuzumab-ADC-24-9 payload
Undisclosed
Nimotuzumab-ADC-24-9 linker
[52]
Nimotuzumab-ADC-24-10
Nimotuzumab-ADC-24-10 payload
Undisclosed
Nimotuzumab-ADC-24-10 linker
[52]
Nimotuzumab-ADC-24-11
Nimotuzumab-ADC-24-11 payload
Undisclosed
Nimotuzumab-ADC-24-11 linker
[52]
Nimotuzumab-ADC-24-12
Nimotuzumab-ADC-24-12 payload
Undisclosed
Nimotuzumab-ADC-24-12 linker
[52]
Nimotuzumab-ADC-24-13
Nimotuzumab-ADC-24-13 payload
Undisclosed
Nimotuzumab-ADC-24-13 linker
[52]
Nimotuzumab-ADC-Tb5-1
Nimotuzumab-ADC-Tb5-1 payload
Undisclosed
Nimotuzumab-ADC-Tb5-1 linker
[21]
Nimotuzumab-ADC-Tb5-2
Nimotuzumab-ADC-Tb5-2 payload
Undisclosed
Nimotuzumab-ADC-Tb5-2 linker
[21]
Nimotuzumab-Compound 9
Mertansine DM1
Microtubule (MT)
Nimotuzumab-Compound 9 linker
[36]
Nimotuzumab-Compound 17
Mertansine DM4
Microtubule (MT)
Nimotuzumab-Compound 17 linker
[36]
Nimotuzumab-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Nimotuzumab-Compound 25 linker
[36]
Nimotuzumab-Compound 31
Auristatin 0101
Microtubule (MT)
Nimotuzumab-Compound 31 linker
[36]
Nimotuzumab-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Nimotuzumab-Compound 36 linker
[36]
Nimotuzumab-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Nimotuzumab-Compound 43 linker
[36]
Nimotuzumab-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Nimotuzumab-Compound 49 linker
[36]
Nimotuzumab-Compound 55
Mertansine DM1
Microtubule (MT)
Nimotuzumab-Compound 55 linker
[36]
Nimotuzumab-Compound 59
Mertansine DM4
Microtubule (MT)
Nimotuzumab-Compound 59 linker
[36]
Nimotuzumab-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Nimotuzumab-Compound 64 linker
[36]
Nimotuzumab-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Nimotuzumab-Compound 69 linker
[36]
Nimotuzumab-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Nimotuzumab-Compound 74 linker
[36]
Nimotuzumab-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Nimotuzumab-Compound 75 linker
[36]
Nimotuzumab-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Nimotuzumab-Compound 76 linker
[36]
Nimotuzumab-Compound 77
Mertansine DM1
Microtubule (MT)
Nimotuzumab-Compound 77 linker
[36]
Nimotuzumab-Compound 78
Auristatin 0101
Microtubule (MT)
Nimotuzumab-Compound 78 linker
[36]
Nimotuzumab-Compound 79
Auristatin 0101
Microtubule (MT)
Nimotuzumab-Compound 79 linker
[36]
Nimotuzumab-Compound 80
Mertansine DM4
Microtubule (MT)
Nimotuzumab-Compound 80 linker
[36]
CN114917361A ADC-3
CN114917361A ADC-3 payload
Undisclosed
CN114917361A ADC-3 linker
[37]
Panitumumab
ADC Info ADC Name Payload Target Linker Ref
CyEt-Pan-Duo
DEAEA duocarmycin
Human Deoxyribonucleic acid (hDNA)
Mal-PEG4-Triazol-Cyanine cage
[53]
Panitumumab-ADC-Tb5-1
Panitumumab-ADC-Tb5-1 payload
Undisclosed
Panitumumab-ADC-Tb5-1 linker
[21]
Panitumumab-ADC-Tb5-2
Panitumumab-ADC-Tb5-2 payload
Undisclosed
Panitumumab-ADC-Tb5-2 linker
[21]
AVID-300
Mertansine DM1
Microtubule (MT)
Undisclosed
[54]
Panitumumab-DNA conjugate
DNA mimics
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[28]
Panitumumab-Compound 9
Mertansine DM1
Microtubule (MT)
Panitumumab-Compound 9 linker
[36]
Panitumumab-Compound 17
Mertansine DM4
Microtubule (MT)
Panitumumab-Compound 17 linker
[36]
Panitumumab-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Panitumumab-Compound 25 linker
[36]
Panitumumab-Compound 31
Auristatin 0101
Microtubule (MT)
Panitumumab-Compound 31 linker
[36]
Panitumumab-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Panitumumab-Compound 36 linker
[36]
Panitumumab-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Panitumumab-Compound 43 linker
[36]
Panitumumab-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Panitumumab-Compound 49 linker
[36]
Panitumumab-Compound 55
Mertansine DM1
Microtubule (MT)
Panitumumab-Compound 55 linker
[36]
Panitumumab-Compound 59
Mertansine DM4
Microtubule (MT)
Panitumumab-Compound 59 linker
[36]
Panitumumab-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Panitumumab-Compound 64 linker
[36]
Panitumumab-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Panitumumab-Compound 69 linker
[36]
Panitumumab-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Panitumumab-Compound 74 linker
[36]
Panitumumab-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Panitumumab-Compound 75 linker
[36]
Panitumumab-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Panitumumab-Compound 76 linker
[36]
Panitumumab-Compound 77
Mertansine DM1
Microtubule (MT)
Panitumumab-Compound 77 linker
[36]
Panitumumab-Compound 78
Auristatin 0101
Microtubule (MT)
Panitumumab-Compound 78 linker
[36]
Panitumumab-Compound 79
Auristatin 0101
Microtubule (MT)
Panitumumab-Compound 79 linker
[36]
Panitumumab-Compound 80
Mertansine DM4
Microtubule (MT)
Panitumumab-Compound 80 linker
[36]
Pimurutamab
ADC Info ADC Name Payload Target Linker Ref
Pimurutamab-ADC-Tb5-1
Pimurutamab-ADC-Tb5-1 payload
Undisclosed
Pimurutamab-ADC-Tb5-1 linker
[21]
Pimurutamab-ADC-Tb5-2
Pimurutamab-ADC-Tb5-2 payload
Undisclosed
Pimurutamab-ADC-Tb5-2 linker
[21]
ADC Info ADC Name Payload Target Linker Ref
RC68-PY-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
PY-VC-PABC
[55]
RC68-Mc-Val-Cit-PABC-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[55]
Serclutamab
ADC Info ADC Name Payload Target Linker Ref
Serclutamab talirine
SGD-1882
Human Deoxyribonucleic acid (hDNA)
Mc-Val-Ala
[56]
Serclutamab-ADC-Tb5-1
Serclutamab-ADC-Tb5-1 payload
Undisclosed
Serclutamab-ADC-Tb5-1 linker
[21]
Serclutamab-ADC-Tb5-2
Serclutamab-ADC-Tb5-2 payload
Undisclosed
Serclutamab-ADC-Tb5-2 linker
[21]
Tomuzotuximab
ADC Info ADC Name Payload Target Linker Ref
Tomuzotuximab-ADC-Tb5-1
Tomuzotuximab-ADC-Tb5-1 payload
Undisclosed
Tomuzotuximab-ADC-Tb5-1 linker
[21]
Tomuzotuximab-ADC-Tb5-2
Tomuzotuximab-ADC-Tb5-2 payload
Undisclosed
Tomuzotuximab-ADC-Tb5-2 linker
[21]
Zalutumumab
ADC Info ADC Name Payload Target Linker Ref
Zalutumumab-ADC-Tb5-1
Zalutumumab-ADC-Tb5-1 payload
Undisclosed
Zalutumumab-ADC-Tb5-1 linker
[21]
Zalutumumab-ADC-Tb5-2
Zalutumumab-ADC-Tb5-2 payload
Undisclosed
Zalutumumab-ADC-Tb5-2 linker
[21]
Undisclosed
ADC Info ADC Name Payload Target Linker Ref
BB-1705
Eribulin
Microtubule (MT)
Undisclosed
[57]
EGFR-EDV-RRM1
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Undisclosed
[58]
HLX-42
Undisclosed
Undisclosed
Undisclosed
[59]
HTI-1511
Undisclosed
Undisclosed
Undisclosed
[60]
Recombinant humanized anti-EGFR mAb-DUO-5 conjugate
Duostatin 5
Human Deoxyribonucleic acid (hDNA)
Undisclosed
[61]
Probody drug conjugate (CytomX Therapeutics)
Undisclosed
Undisclosed
Undisclosed
[62]
PBX-003
Undisclosed
Undisclosed
Undisclosed
[63]
NS Cys-vc-MMAE
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
[31]
STI-A020X
Undisclosed
Undisclosed
Undisclosed
[64]
Tissue/Disease specific Abundances of This Antigen
Tissue specific Abundances of This Antigen
ICD Disease Classification 01
Click to Show/Hide the 1 Disease of This Class
Bacterial infection [ICD-11: 1A00-1C4Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gingival
The Specific Disease Bacterial infection of gingival
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.121787504; Fold-change: -0.254498943; Z-score: -0.419900828
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 02
Click to Show/Hide the 22 Disease of This Class
Brain cancer [ICD-11: 2A00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Brainstem
The Specific Disease Glioma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 2.09E-05; Fold-change: 0.396422438; Z-score: 190.0757185
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue White matter
The Specific Disease Glioma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000631625; Fold-change: 0.387503368; Z-score: 1.694165237
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Brainstem
The Specific Disease Neuroectodermal tumor
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 1.84E-08; Fold-change: -1.120738166; Z-score: -4.445591048
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Nervous
The Specific Disease Brain cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 8.30E-26; Fold-change: 0.062080465; Z-score: 0.13172412
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic myeloid leukemia [ICD-11: 2A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Polycythemia vera
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.023361705; Fold-change: 0.035974971; Z-score: 0.227643588
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Whole blood
The Specific Disease Myelofibrosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.780007905; Fold-change: -0.012254581; Z-score: -0.090792428
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
MyeloDysplastic syndromes [ICD-11: 2A37]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Myelodysplastic syndromes
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.245724038; Fold-change: 0.010369981; Z-score: 0.049585497
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.168196738; Fold-change: -0.06784742; Z-score: -0.779471035
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Lymphoma [ICD-11: 2A90- 2A85]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Tonsil
The Specific Disease Lymphoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.382643541; Fold-change: -0.113681087; Z-score: -0.315728038
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Gastric cancer [ICD-11: 2B72]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gastric
The Specific Disease Gastric cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.252471843; Fold-change: -0.417321215; Z-score: -2.17289188
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 5.61E-08; Fold-change: 0.32109048; Z-score: 1.408689643
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Colon cancer [ICD-11: 2B90]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Colon
The Specific Disease Colon cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 5.14E-21; Fold-change: -0.549885654; Z-score: -1.154337396
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.48E-05; Fold-change: -0.209904054; Z-score: -0.392291048
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pancreatic cancer [ICD-11: 2C10]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Pancreas
The Specific Disease Pancreatic cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.03639932; Fold-change: -0.64126062; Z-score: -1.023741138
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.001755119; Fold-change: -0.285448426; Z-score: -0.648715881
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Liver cancer [ICD-11: 2C12]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Liver
The Specific Disease Liver cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 2.70E-06; Fold-change: -0.504393522; Z-score: -1.087146684
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.033310941; Fold-change: -0.131769897; Z-score: -0.267655476
The Expression Level of Disease Section Compare with the Other Disease Section p-value: 0.608500766; Fold-change: -0.18721522; Z-score: -0.18802746
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Lung cancer [ICD-11: 2C25]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Lung
The Specific Disease Lung cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.164956308; Fold-change: -0.042320445; Z-score: -0.085238641
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.001575769; Fold-change: -0.213812939; Z-score: -0.347873589
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Melanoma [ICD-11: 2C30]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Melanoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.160431517; Fold-change: -0.338741165; Z-score: -0.229797397
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sarcoma [ICD-11: 2C35]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Muscle
The Specific Disease Sarcoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 3.73E-07; Fold-change: -0.312000231; Z-score: -0.878853628
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.000108127; Fold-change: -1.098281997; Z-score: -7.394373073
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Breast cancer [ICD-11: 2C60]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Breast
The Specific Disease Breast cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 1.04E-65; Fold-change: -0.887115361; Z-score: -1.532278
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 2.77E-16; Fold-change: -0.949187635; Z-score: -1.790429737
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ovarian cancer [ICD-11: 2C73]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Ovarian
The Specific Disease Ovarian cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.925191665; Fold-change: -0.010248209; Z-score: -0.026218784
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 6.76E-06; Fold-change: -1.284050058; Z-score: -2.322986612
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Cervical cancer [ICD-11: 2C77]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Cervical
The Specific Disease Cervical cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.769460628; Fold-change: 0.010058153; Z-score: 0.021355021
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Uterine cancer [ICD-11: 2C78]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Endometrium
The Specific Disease Uterine cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 1.71E-09; Fold-change: 0.623510206; Z-score: 0.938068284
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.390101917; Fold-change: -0.057920151; Z-score: -0.123770742
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Prostate cancer [ICD-11: 2C82]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Prostate
The Specific Disease Prostate cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000743224; Fold-change: -0.592164553; Z-score: -0.822129897
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Bladder cancer [ICD-11: 2C94]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bladder
The Specific Disease Bladder cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.58673616; Fold-change: 0.085155974; Z-score: 0.286686437
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Retina cancer [ICD-11: 2D02]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Uvea
The Specific Disease Retinoblastoma tumor
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 7.30E-06; Fold-change: -0.662124792; Z-score: -2.090981006
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Thyroid cancer [ICD-11: 2D10]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Thyroid
The Specific Disease Thyroid cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.683903471; Fold-change: -0.029613946; Z-score: -0.057603505
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.68E-08; Fold-change: 0.500840739; Z-score: 1.453378587
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Adrenal cancer [ICD-11: 2D11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Adrenal cortex
The Specific Disease Adrenocortical carcinoma
The Expression Level of Disease Section Compare with the Other Disease Section p-value: 0.109089592; Fold-change: 0.031285712; Z-score: 0.129918335
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Head and neck cancer [ICD-11: 2D42]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Head and neck
The Specific Disease Head and neck cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 5.84E-05; Fold-change: 0.319225343; Z-score: 0.547839158
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pituitary cancer [ICD-11: 2F37]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Pituitary
The Specific Disease Pituitary gonadotrope tumor
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.015412629; Fold-change: -0.489406007; Z-score: -1.140504972
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Pituitary
The Specific Disease Pituitary cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.122089427; Fold-change: -0.293885551; Z-score: -0.80993597
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 03
Click to Show/Hide the 1 Disease of This Class
Thrombocytopenia [ICD-11: 3B64]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Thrombocytopenia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.942721697; Fold-change: -0.042865227; Z-score: -0.191437293
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 04
Click to Show/Hide the 2 Disease of This Class
Lupus erythematosus [ICD-11: 4A40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Lupus erythematosus
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.060176056; Fold-change: -0.170491985; Z-score: -0.261805293
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Autoimmune disease [ICD-11: 4A4Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral monocyte
The Specific Disease Autoimmune uveitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.634565667; Fold-change: 0.029451646; Z-score: 0.140909164
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 05
Click to Show/Hide the 1 Disease of This Class
Hyperlipoproteinaemia [ICD-11: 5C80]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Familial hypercholesterolemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000346456; Fold-change: -0.350577711; Z-score: -0.993142958
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 06
Click to Show/Hide the 1 Disease of This Class
Schizophrenia [ICD-11: 6A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Superior temporal cortex
The Specific Disease Schizophrenia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.23777059; Fold-change: -0.084417876; Z-score: -0.573046233
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 08
Click to Show/Hide the 3 Disease of This Class
Multiple sclerosis [ICD-11: 8A40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Spinal cord
The Specific Disease Multiple sclerosis
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.520674685; Fold-change: -0.119960855; Z-score: -0.442952499
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Plasmacytoid dendritic cells
The Specific Disease Multiple sclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.474407287; Fold-change: 0.195749632; Z-score: 0.662938559
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Epilepsy [ICD-11: 8A60]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peritumoral cortex
The Specific Disease Epilepsy
The Expression Level of Disease Section Compare with the Other Disease Section p-value: 0.659908366; Fold-change: 0.078503686; Z-score: 0.435042009
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Cerebral ischaemic stroke [ICD-11: 8B11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Cardioembolic Stroke
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.39698865; Fold-change: 0.035946392; Z-score: 0.19461223
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Peripheral blood
The Specific Disease Ischemic stroke
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.073526156; Fold-change: 0.108240012; Z-score: 0.73718389
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 1
Click to Show/Hide the 6 Disease of This Class
HIV [ICD-11: 1C60-1C62]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue White matter
The Specific Disease HIV
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.133889529; Fold-change: -0.176283458; Z-score: -0.387609293
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Influenza [ICD-11: 1E30]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Influenza
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.139528889; Fold-change: 0.412341351; Z-score: 1.852115602
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic hepatitis C [ICD-11: 1E51.1]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Chronic hepatitis C
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.582291712; Fold-change: 0.047900891; Z-score: 0.46130085
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sepsis [ICD-11: 1G40-1G41]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Sepsis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.402318482; Fold-change: 0.039282315; Z-score: 0.13131953
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Septic shock [ICD-11: 1G41]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Septic shock
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.086003296; Fold-change: 0.069049426; Z-score: 0.200171879
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pediatric respiratory syncytial virus infection [ICD-11: CA40.11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Pediatric respiratory syncytial virus infection
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.395692091; Fold-change: -0.06026284; Z-score: -0.455226207
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 11
Click to Show/Hide the 6 Disease of This Class
Essential hypertension [ICD-11: BA00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Essential hypertension
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.741457622; Fold-change: 0.066107405; Z-score: 0.417449878
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Myocardial infarction [ICD-11: BA41]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Myocardial infarction
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.176114839; Fold-change: 0.198467306; Z-score: 0.232030886
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Coronary artery disease [ICD-11: BA8Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Coronary artery disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.314246566; Fold-change: -0.117301611; Z-score: -0.664369762
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Aortic stenosis [ICD-11: BB70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Calcified aortic valve
The Specific Disease Aortic stenosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.130891099; Fold-change: -0.540734048; Z-score: -1.146145153
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Arteriosclerosis [ICD-11: BD40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Arteriosclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.696195472; Fold-change: -0.002257291; Z-score: -0.014839449
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Aneurysm [ICD-11: BD50]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Intracranial artery
The Specific Disease Aneurysm
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.712803996; Fold-change: 0.021868361; Z-score: 0.07116771
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 12
Click to Show/Hide the 8 Disease of This Class
Immunodeficiency [ICD-11: 4A00-4A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Immunodeficiency
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.258565971; Fold-change: 0.061648407; Z-score: 0.539830147
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Apnea [ICD-11: 7A40]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Hyperplastic tonsil
The Specific Disease Apnea
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.204433132; Fold-change: -0.516404571; Z-score: -1.886059739
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Olive pollen allergy [ICD-11: CA08.00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Olive pollen allergy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.022020098; Fold-change: 0.07425653; Z-score: 0.747551657
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic rhinosinusitis [ICD-11: CA0A]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Sinus mucosa
The Specific Disease Chronic rhinosinusitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.259827013; Fold-change: -0.146718283; Z-score: -0.51397612
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Chronic obstructive pulmonary disease [ICD-11: CA22]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Lung
The Specific Disease Chronic obstructive pulmonary disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.025955331; Fold-change: 0.299929709; Z-score: 0.559328432
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Small airway epithelium
The Specific Disease Chronic obstructive pulmonary disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 1.48E-05; Fold-change: -0.377524026; Z-score: -0.569260054
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Asthma [ICD-11: CA23]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Nasal and bronchial airway
The Specific Disease Asthma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.000167329; Fold-change: -0.029477334; Z-score: -0.025194139
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Human rhinovirus infection [ICD-11: CA42]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Nasal Epithelium
The Specific Disease Human rhinovirus infection
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.502808824; Fold-change: 0.01809045; Z-score: 0.091197206
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Idiopathic pulmonary fibrosis [ICD-11: CB03.4]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Lung
The Specific Disease Idiopathic pulmonary fibrosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.284675553; Fold-change: -0.211015104; Z-score: -1.280194482
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 13
Click to Show/Hide the 5 Disease of This Class
Periodontal disease [ICD-11: DA0C]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gingival
The Specific Disease Periodontal disease
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.881106979; Fold-change: -0.029473829; Z-score: -0.057108694
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Eosinophilic gastritis [ICD-11: DA42.2]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Gastric antrum
The Specific Disease Eosinophilic gastritis
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.069975734; Fold-change: 0.210013435; Z-score: 1.295629095
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Liver failure [ICD-11: DB99.7-DB99.8]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Liver
The Specific Disease Liver failure
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.693235121; Fold-change: -0.121806232; Z-score: -0.428675273
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ulcerative colitis [ICD-11: DD71]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Colon mucosal
The Specific Disease Ulcerative colitis
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.128069098; Fold-change: -0.582105542; Z-score: -0.634041508
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Irritable bowel syndrome [ICD-11: DD91.0]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Rectal colon
The Specific Disease Irritable bowel syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.04321468; Fold-change: -0.108196459; Z-score: -0.240973064
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 14
Click to Show/Hide the 5 Disease of This Class
Atopic dermatitis [ICD-11: EA80]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Atopic dermatitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.607264349; Fold-change: -0.037926194; Z-score: -0.150138764
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Psoriasis [ICD-11: EA90]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Psoriasis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 1.86E-07; Fold-change: -0.273914732; Z-score: -0.422333791
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.31E-21; Fold-change: 1.020001767; Z-score: 1.933164624
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Vitiligo [ICD-11: ED63.0]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Vitiligo
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.039775146; Fold-change: -0.12804772; Z-score: -1.523423318
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Alopecia [ICD-11: ED70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin from scalp
The Specific Disease Alopecia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.761815148; Fold-change: 0.010639659; Z-score: 0.023002255
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sensitive skin [ICD-11: EK0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Sensitive skin
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.218614761; Fold-change: 0.115539239; Z-score: 0.433164694
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 15
Click to Show/Hide the 6 Disease of This Class
Osteoarthritis [ICD-11: FA00-FA0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Synovial
The Specific Disease Osteoarthritis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.374847232; Fold-change: -0.43201832; Z-score: -0.514913639
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Arthropathy [ICD-11: FA00-FA5Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Arthropathy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.081997621; Fold-change: 0.093549116; Z-score: 0.578331579
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Arthritis [ICD-11: FA20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Arthritis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.660682419; Fold-change: 0.011173661; Z-score: 0.080134733
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Rheumatoid arthritis [ICD-11: FA20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Synovial
The Specific Disease Rheumatoid arthritis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.122507686; Fold-change: -0.125025436; Z-score: -0.217847322
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ankylosing spondylitis [ICD-11: FA92.0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Pheripheral blood
The Specific Disease Ankylosing spondylitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.158435174; Fold-change: -0.062122187; Z-score: -1.017017264
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Osteoporosis [ICD-11: FB83]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Osteoporosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.445033355; Fold-change: 0.159205073; Z-score: 0.271891529
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 16
Click to Show/Hide the 2 Disease of This Class
Endometriosis [ICD-11: GA10]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Endometrium
The Specific Disease Endometriosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.439314111; Fold-change: -0.042348765; Z-score: -0.111463532
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Interstitial cystitis [ICD-11: GC00.3]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bladder
The Specific Disease Interstitial cystitis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.009627001; Fold-change: -0.491183087; Z-score: -1.395256103
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 19
Click to Show/Hide the 1 Disease of This Class
Preterm birth [ICD-11: KA21.4Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Myometrium
The Specific Disease Preterm birth
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.818446567; Fold-change: 0.232284409; Z-score: 0.329395343
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 2
Click to Show/Hide the 8 Disease of This Class
Acute myelocytic leukemia [ICD-11: 2A60]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Acute myelocytic leukemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.004841358; Fold-change: 0.05212256; Z-score: 0.265545336
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Myeloma [ICD-11: 2A83]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Myeloma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.003869536; Fold-change: -0.239001275; Z-score: -1.376881647
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Peripheral blood
The Specific Disease Myeloma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.208147725; Fold-change: 0.177778545; Z-score: 0.795850504
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Oral cancer [ICD-11: 2B6E]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Oral
The Specific Disease Oral cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.212472997; Fold-change: 0.032061442; Z-score: 0.041211697
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.993394276; Fold-change: -0.043058508; Z-score: -0.06018442
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Esophagal cancer [ICD-11: 2B70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Esophagus
The Specific Disease Esophagal cancer
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.744114966; Fold-change: -0.927773326; Z-score: -1.08206894
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Rectal cancer [ICD-11: 2B92]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Rectal colon
The Specific Disease Rectal cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.010708348; Fold-change: -0.247293493; Z-score: -1.631764056
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.000124299; Fold-change: -0.588712023; Z-score: -3.166205249
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Skin cancer [ICD-11: 2C30-2C3Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Skin cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 2.11E-56; Fold-change: -1.777974925; Z-score: -2.29660524
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 1.45E-13; Fold-change: -0.830092946; Z-score: -1.578689736
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Renal cancer [ICD-11: 2C90-2C91]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Kidney
The Specific Disease Renal cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.344182483; Fold-change: -0.222447507; Z-score: -0.552134691
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.141472764; Fold-change: -0.30395708; Z-score: -0.480230635
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Ureter cancer [ICD-11: 2C92]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Urothelium
The Specific Disease Ureter cancer
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.534150833; Fold-change: -0.07320583; Z-score: -0.70982248
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 20
Click to Show/Hide the 2 Disease of This Class
Simpson golabi behmel syndrome [ICD-11: LD2C]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Adipose
The Specific Disease Simpson golabi behmel syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.532863679; Fold-change: 0.260946163; Z-score: 0.844238137
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Tuberous sclerosis complex [ICD-11: LD2D.2]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Perituberal
The Specific Disease Tuberous sclerosis complex
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.076094338; Fold-change: 0.246412841; Z-score: 1.045838611
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 3
Click to Show/Hide the 3 Disease of This Class
Anemia [ICD-11: 3A00-3A9Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Bone marrow
The Specific Disease Anemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.056871452; Fold-change: 0.714282409; Z-score: 1.667897026
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sickle cell disease [ICD-11: 3A51.0-3A51.3]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Sickle cell disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.277108; Fold-change: 0.095389332; Z-score: 0.392017394
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Thrombocythemia [ICD-11: 3B63]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Thrombocythemia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.203720308; Fold-change: 0.06210334; Z-score: 0.408177455
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 4
Click to Show/Hide the 4 Disease of This Class
Scleroderma [ICD-11: 4A42.Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Scleroderma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.017626982; Fold-change: -0.16727954; Z-score: -1.270306628
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Sjogren syndrome [ICD-11: 4A43]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Salivary gland
The Specific Disease Sjogren syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.219555624; Fold-change: 0.401515374; Z-score: 0.802727293
The Expression Level of Disease Section Compare with the Adjacent Tissue p-value: 0.002961811; Fold-change: -0.842359448; Z-score: -2.480067337
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Behcet disease [ICD-11: 4A62]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Peripheral blood
The Specific Disease Behcet disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.596404505; Fold-change: -0.018694152; Z-score: -0.097984568
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Autosomal dominant monocytopenia [ICD-11: 4B04]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Autosomal dominant monocytopenia
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.778417804; Fold-change: -0.053832; Z-score: -0.46066501
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 5
Click to Show/Hide the 5 Disease of This Class
Type 2 diabetes [ICD-11: 5A11]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Liver
The Specific Disease Type 2 diabetes
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.949677634; Fold-change: -0.406337736; Z-score: -0.511049171
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Polycystic ovary syndrome [ICD-11: 5A80.1]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Vastus lateralis muscle
The Specific Disease Polycystic ovary syndrome
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.546835014; Fold-change: -0.06801586; Z-score: -0.280234912
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Obesity [ICD-11: 5B81]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Subcutaneous Adipose
The Specific Disease Obesity
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.124507134; Fold-change: -0.078661149; Z-score: -0.36928348
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Pompe disease [ICD-11: 5C51.3]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Biceps muscle
The Specific Disease Pompe disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.144693726; Fold-change: 0.282351398; Z-score: 0.912041551
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Batten disease [ICD-11: 5C56.1]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Batten disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.051539027; Fold-change: 0.098915352; Z-score: 1.441146048
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 6
Click to Show/Hide the 2 Disease of This Class
Autism [ICD-11: 6A02]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Autism
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.058857611; Fold-change: -0.104536145; Z-score: -0.500851731
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Anxiety disorder [ICD-11: 6B00-6B0Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Anxiety disorder
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.92299867; Fold-change: -0.020057963; Z-score: -0.099634657
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
ICD Disease Classification 8
Click to Show/Hide the 7 Disease of This Class
Parkinson disease [ICD-11: 8A00]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Substantia nigra
The Specific Disease Parkinson disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.892864426; Fold-change: 0.087279758; Z-score: 0.228343572
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Huntington disease [ICD-11: 8A01]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Huntington disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.007018374; Fold-change: 0.16800984; Z-score: 1.202443013
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Alzheimer disease [ICD-11: 8A20]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Entorhinal cortex
The Specific Disease Alzheimer disease
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 2.67E-05; Fold-change: 0.17669589; Z-score: 0.555604455
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Seizure [ICD-11: 8A60-8A6Z]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Whole blood
The Specific Disease Seizure
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.982857988; Fold-change: -0.002190559; Z-score: -0.010466464
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Lateral sclerosis [ICD-11: 8B60.4]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Skin
The Specific Disease Lateral sclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.108235245; Fold-change: -0.815041646; Z-score: -1.653864007
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
The Studied Tissue Cervical spinal cord
The Specific Disease Lateral sclerosis
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.816613059; Fold-change: 0.013862287; Z-score: 0.066052452
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Muscular atrophy [ICD-11: 8C70]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Muscle
The Specific Disease Muscular atrophy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.605459319; Fold-change: 0.061419252; Z-score: 0.208202258
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
Myopathy [ICD-11: 8C70.6]
Click to Show/Hide
Differential expression pattern of antigen in diseases
The Studied Tissue Muscle
The Specific Disease Myopathy
The Expression Level of Disease Section Compare with the Healthy Individual Tissue p-value: 0.358729957; Fold-change: 0.11474649; Z-score: 0.327795785
Disease-specific Antigen Abundances Click to View the Clearer Original Diagram
References
Ref 1 Click Chemistry-Generated Auristatin F-Linker-Benzylguanine for a SNAP-Tag-Based Recombinant Antibody-Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells. ACS Omega. 2023 Jan 17;8(4):4026-4037. doi: 10.1021/acsomega.2c06844. eCollection 2023 Jan 31.
Ref 2 A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5.
Ref 3 Anti-egfr antibodies and antibody drug conjugates.
Ref 4 EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing. Biol Chem. 2021 Sep 20;403(5-6):525-534.
Ref 5 Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. Eng Life Sci. 2020 Oct 7;21(1-2):37-44. doi: 10.1002/elsc.202000027. eCollection 2021 Jan.
Ref 6 Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Mol Pharm. 2019 Dec 2;16(12):4817-4825. doi: 10.1021/acs.molpharmaceut.9b00696. Epub 2019 Oct 29.
Ref 7 Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett. 2019 Jul 22;10(8):1211-1215. doi: 10.1021/acsmedchemlett.9b00254. eCollection 2019 Aug 8.
Ref 8 Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 9 Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies. Mol Cancer Ther. 2019 Jun;18(6):1104-1114. doi: 10.1158/1535-7163.MCT-18-0854.
Ref 10 Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun. 2006 Oct 20;349(2):816-24. doi: 10.1016/j.bbrc.2006.08.114. Epub 2006 Aug 28.
Ref 11 Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget. 2019 Feb 1;10(10):1031-1044. doi: 10.18632/oncotarget.26613. eCollection 2019 Feb 1.
Ref 12 Antibody-drug conjugate; 2016-08-25.
Ref 13 Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx. 2023 Aug;50(4):641-645. doi: 10.1016/j.anl.2022.06.004. Epub 2022 Jun 29.
Ref 14 A new class of DNA sequence-selective G-A cross-linking antibody-drug conjugate (ADC) payloads. Cancer Res (2022) 82 (12_Supplement): 1749.
Ref 15 Tumor-targeted delivery of a STING agonist improvescancer immunotherapy. Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2214278119.
Ref 16 Conjugation of Cetuximab - Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines. Asian Pac J Cancer Prev. 2022 May 1;23(5):1803-1812.
Ref 17 An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett. 2023 Feb 1;554:216024.
Ref 18 Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. Bioconjug Chem. 2022 Aug 17;33(8):1474-1484.
Ref 19 EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy. Int J Nanomedicine. 2021 Mar 26;16:2443-2459. doi: 10.2147/IJN.S289228. eCollection 2021.
Ref 20 Compounds, linker-drugs and ligand-drug conjugates; 2020-06-16
Ref 21 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.
Ref 22 Neodegrader conjugates; 2021-10-07.
Ref 23 Antibody-drug conjugates comprising branched linkers and methods related thereto; 2017-06-01.
Ref 24 Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab. J Immunother Cancer. 2022 Dec;10(12):e005660.
Ref 25 A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. Toxins (Basel). 2023 Jan 9;15(1):57. doi: 10.3390/toxins15010057.
Ref 26 Development of a new minimally invasive phototherapy for lung cancer using antibody-toxin conjugate. Thorac Cancer. 2023 Mar;14(7):645-653. doi: 10.1111/1759-7714.14776. Epub 2023 Jan 19.
Ref 27 Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II. Mol Ther Oncolytics. 2020 Jul 6;18:304-316. doi: 10.1016/j.omto.2020.07.001. eCollection 2020 Sep 25.
Ref 28 Aptamer-Directed Conjugation of DNA to Therapeutic Antibodies. Bioconjug Chem. 2019 Aug 21;30(8):2127-2135. doi: 10.1021/acs.bioconjchem.9b00363. Epub 2019 Jul 12.
Ref 29 Camptothecin derivative and ligand-drug conjugate thereof; 2022-04-21.
Ref 30 Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility. Antibodies (Basel). 2018 Mar 22;7(2):15. doi: 10.3390/antib7020015.
Ref 31 MAbs. 2023 Jan-Dec;15(1):2149057. doi: 10.1080/19420862.2022.2149057.
Ref 32 Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) c-MET Antibodies and Antibody-Drug Conjugates. J Biol Chem. 2016 Nov 25;291(48):25106-25119. doi: 10.1074/jbc.M116.753491. Epub 2016 Sep 30.
Ref 33 Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Br J Cancer. 2020 Nov;123(10):1502-1512. doi: 10.1038/s41416-020-01046-6. Epub 2020 Sep 11.
Ref 34 Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates. Bioorg Med Chem. 2020 Dec 1;28(23):115793. doi: 10.1016/j.bmc.2020.115793. Epub 2020 Oct 6.
Ref 35 Conjugates comprising self-immolative groups and methods related thereto.
Ref 36 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 37 Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen.
Ref 38 Introduction to basic information on ADC drug ADC-W-2589.
Ref 39 Compositions and methods related to anti-egfr antibody drug conjugates; 2017-03-30.
Ref 40 Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Cancer Sci. 2021 Dec;112(12):5020-5033. doi: 10.1111/cas.15153. Epub 2021 Oct 30.
Ref 41 Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel). 2020 Oct 2;13(10):289. doi: 10.3390/ph13100289.
Ref 42 RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models. Oncotarget. 2018 Sep 11;9(71):33446-33458. doi: 10.18632/oncotarget.26002. eCollection 2018 Sep 11.
Ref 43 Bispecific anti-mPDGFR x cotinine scFv-C()-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR expressing cells. Methods. 2019 Feb 1;154:125-135. doi: 10.1016/j.ymeth.2018.10.002. Epub 2018 Oct 4.
Ref 44 A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022 Dec;29(1):1243-1256.
Ref 45 First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3550-3550.
Ref 46 Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018 Jul;70(7):841-854. doi: 10.1111/jphp.12911. Epub 2018 Mar 25.
Ref 47 A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs. 2020 Oct;38(5):1483-1494.
Ref 48 Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021 Dec 9;8(1):63.
Ref 49 Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer. J Med Chem. 2022 May 26;65(10):7141-7153. doi: 10.1021/acs.jmedchem.1c01920. Epub 2022 May 6.
Ref 50 AVID100 is an anti-EGFR ADC that promotes DM1-meditated cytotoxicity on cancer cells but not on normal cells. Cancer Res (2019) 79 (13_Supplement): 218. doi: 10.1158/1538-7445.AM2019-218.
Ref 51 Preclinical evaluation of NC-6201, an antibody/drug-conjugated micelle incorporating novel hemiasterlin analogue E7974.
Ref 52 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.
Ref 53 In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. ACS Cent Sci. 2017 Apr 26;3(4):329-337. doi: 10.1021/acscentsci.7b00026. Epub 2017 Feb 24.
Ref 54 ADC review AVID-300
Ref 55 Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2019 Jul;84(1):61-72. doi: 10.1007/s00280-019-03848-9. Epub 2019 Apr 29.
Ref 56 Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neurooncol Adv. 2022 Dec 21;5(1):vdac183.
Ref 57 A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors; NCT05217693.
Ref 58 Introduction to basic information on antibody-drug nanocell conjugates(EnGeneIC Pty Ltd.).
Ref 59 Introduction to basic information on ADC drug HLX-42.
Ref 60 Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors. Cancer Res (2016) 76 (14_Supplement): 1217.
Ref 61 Introduction to basic information on recombinant humanized anti-EGFR mAb-DUO-5 conjugate(Zova Biotherapeutics/Zhejiang Hisun Pharmaceutical).
Ref 62 Introduction to basic information on ADC drug Probody drug conjugate (CytomX Therapeutics)
Ref 63 Pinotbio biotechnology company product pipeline
Ref 64 Sorrento therapeutics next-generation cancer therapeutics; November 2013

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.